Exposure, D-Cycloserine Enhancement, and Genetic Modulators in Panic Disorder
Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
This is a 5-year double blind, randomized, controlled, trial conducted at three treatment
sites, aimed at showing the acute and longer-term effects of DCS augmentation of
exposure-based CBT for panic disorder relative to placebo augmentation. By demonstrating that
DCS can enhance the results of even a brief treatment strategy, the investigators are seeking
to validate an approach that fits well with the practice limitations and applications of CBT
in effectiveness studies.
Phase:
Phase 2
Details
Lead Sponsor:
Boston University Boston University Charles River Campus
Collaborators:
National Institute of Mental Health (NIMH) National Institute on Drug Abuse (NIDA)